转换从多巴胺受体激动剂卡麦角林:一个开放性试验在128年晚期帕金森患者疾病。
文章的细节
-
引用
复制到剪贴板 -
Linazasoro G
转换从多巴胺受体激动剂卡麦角林:一个开放性试验在128年晚期帕金森患者疾病。
Neuropharmacol。2008; 1 - 2月19到24 (1):31。doi: 10.1097 / wnf.0b013e318067bcc4。
- PubMed ID
-
18303487 (在PubMed]
- 文摘
-
背景:卡麦角林是一个ergotic多巴胺受体激动剂与D2受体活性和很长的半衰期。这个临床药理档案可能会导致不同的效果。小型临床试验表明,一夜之间从1受体激动剂切换到另一个可以安全地执行。目的:确定安全性和有效性在一夜之间从多巴胺受体激动剂转向卡麦角林在晚期帕金森病(PD)患者。方法:晚期帕金森病和运动并发症患者不是最优控制的左旋多巴和稳定剂溴麦角环肽,培高利特,pramipexole,罗匹尼罗在一夜之间被转换为卡麦角林。患者评估使用一个开关日记,统一帕金森病评定量表(分量表I-IV)帕金森病的生活质量8 (PDQ-8),一个特设睡眠问卷调查和一个临时断开期间严重程度问卷调查。等级量表都是管理转换和前2后,6日和12周的治疗,当患者在卡麦角林的最佳剂量。不良反应评估在每个访问检查表。结果:一百二十八例中包括审判。四十是培高利特(平均剂量,2.8 mg / d), 38在pramipexole(平均剂量,2.1 mg / d),和32罗匹尼罗(平均剂量,8.1 mg / d)。 Patients on bromocriptine (n = 18) were excluded from the analysis because of the small sample size. Three patients reported serious side effects (respiratory arrest, dyskinesias, and face edema and abdominal pain). Twenty-eight patients reported 41 adverse events. Twelve patients were withdrawn due to adverse effects (hallucinations [n = 5], dyspnea [n = 1], dizziness [n = 4], and vascular problems [n = 2]). A significant improvement in assessed parameters was obtained (P < 0.0001). Mean levodopa dose remained unchanged. After 12 weeks, the mean dose of cabergoline was 3.2 mg, and 25% of patients were taking the drug twice a day. CONCLUSIONS: Switching from pergolide, ropinirole, and pramipexole to cabergoline in an overnight schedule is safe. The observed clinical improvement may be related to a placebo effect, to the use of low doses of dopamine agonists, or to a direct effect of cabergoline.